Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A major randomized trial just gave doctors clearer guidance on treating AFib patients at intermediate stroke risk. The SINGLE-AF trial found that direct oral anticoagulants (DOACs) cut serious clinical events by 69% compared to no treatment — driven mainly by fewer ischemic strokes — with no uptick in major bleeding. The findings could reshape future cardiology guidelines for this long-uncertain patient group.
For years, cardiologists have faced a tricky question: should atrial fibrillation (AFib) patients at intermediate stroke risk be put on blood thinners? Current ESC guidelines say "consider it" — a recommendation that's left clinicians without clear direction. The SINGLE-AF trial, presented at ESC Congress 2026 and published in the New England Journal of Medicine, finally offers some clarity.
The randomized trial enrolled 1,803 AFib patients in South Korea with an intermediate stroke risk (CHA₂DS₂-VASc score of 1 in men or 2 in women). Half received a direct oral anticoagulant (DOAC) — either apixaban or rivaroxaban — while the other half received no anticoagulation. After 24 months, the results were striking.
By the Numbers:
Why it matters: This is the first randomized trial to show a clear benefit of DOACs in intermediate-risk AFib patients — a group that makes up a significant portion of the AFib population. The results could push future guidelines from "consider it" to a firmer recommendation, and may also influence reimbursement policies for this therapy.
